Personalized add-on treatment after cervical cancer surgery
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests whether a tailored “extra” treatment after surgery—guided by a lab test called minimal residual disease (MRD)—can reduce the risk of cervical cancer coming back. It focuses on people with certain stages of cervical cancer who can follow the treatment plan and study follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have cervical cancer in FIGO stage IB2 to IIA2
- Your overall health is good enough for study participation (ECOG 0 to 2)
- You can understand the study and sign informed consent, and you’ll follow the schedule
- You must be willing to provide samples and medical information at the required time points
- You can’t have another active cancer at the same time (other than cervical cancer)
- You must be able to receive the study’s planned treatment and follow-up tests (like CT or other required scans), without major changes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This study tests a combination of two drugs (camrelizumab and famitinib) given after surgery for early-stage cervical cancer. The goal is to see if this treatment helps keep the cancer from returning. It is for people who have not had any other cancer treatment yet.
This study tests a new drug called zimberelimab, which helps the immune system fight cancer, after standard radiation and chemotherapy for cervical cancer. It might improve the chances of keeping the cancer from coming back.
This trial is testing a new immunotherapy drug (adebrelimab) given along with standard chemoradiation for advanced cervical cancer. The goal is to see if adding this drug improves treatment effectiveness.
This trial tests adding a targeted drug called nimotuzumab to the standard chemoradiotherapy for cervical cancer, followed by ongoing maintenance treatment. It aims to see if this combination helps control the cancer better than chemoradiotherapy alone.
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.